Blar i NTNU Open på forfatter "McDonald, James"

Viser treff 1-5 av 5

    • Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series 

      Vagnildhaug, Ola Magne; Balstad, Trude Rakel; Ottestad, Inger; Bye, Asta; Greil, Christine; Arends, Jann; Baracos, Vickie; Brown, Leo R.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie; Fraser, Eilidh; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Kaasa, Stein; McDonald, James; Philips, Iain; Sayers, Judith; Simpson, Melanie Rae; Sousa, Mariana S.; Skipworth, Richard J.E.; Laird, Barry J.A.; Solheim, Tora S (Journal article; Peer reviewed, 2024)
      There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and ...

    • Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series 

      Yule, Michael S.; Thompson, Joshua; Leesahatsawat, Khachonphat; Sousa, Mariana S.; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Dajani, Olav; Fallon, Marie; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; McDonald, James; McGovern, Josh; Roeland, Eric J.; Sayers, Judith; Skipworth, Richard J.E.; Ottestad, Inger; Philips, Iain; Simpson, Melanie Rae; Solheim, Tora S; Vagnildhaug, Ola Magne; McMillan, Donald; Laird, Barry J; Dolan, Ross D. (Journal article; Peer reviewed, 2024)
      Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement ...

    • Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series 

      Brown, Leo R.; Sousa, Mariana S.; Yule, Michael S.; Baracos, Vickie E.; McMillan, Donald C.; Arends, Jann; Balstad, Trude Rakel; Bye, Asta; Dajani, Olav; Dolan, Ross D.; Fallon, Marie T.; Greil, Christine; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Maddocks, Matthew; McDonald, James; Ottestad, Inger; Phillips, Iain; Sayers, Judith; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Solheim, Tora S; Laird, Barry J; Skipworth, Richard J.E. (Journal article; Peer reviewed, 2024)
      Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most ...

    • Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series 

      McDonald, James; Sayers, Judith; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Baracos, Vickie; Brown, Leo; Bye, Asta; Dajani, Olav; Dolan, Ross; Fallon, Marie T.; Fraser, Eilidh; Griel, Christine; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jamal-Hanjani, Mariam; Jakobsen, Gunnhild; Kaasa, Stein; McMillan, Donald; Maddocks, Matthew; Philips, Iain; Ottestad, Inger; Reid, Kieran F.; Sousa, Mariana S.; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Skipworth, Richard J. E.; Solheim, Tora S; Laird, Barry J (Peer reviewed; Journal article, 2023)
      In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, ...

    • Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series 

      Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Coats, Andrew J.S.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie T.; Greil, Christine; Grzyb, Alexandra; Kaasa, Stein; Koteng, Lisa Heide; May, Anne M.; McDonald, James; Ottestad, Inger; Philips, Iain; Roeland, Eric J.; Sayers, Judith; Simpson, Melanie Rae; Skipworth, Richard J.E.; Solheim, Tora S; Sousa, Mariana S.; Vagnildhaug, Ola Magne; Laird, Barry J.A. (Journal article; Peer reviewed, 2024)
      The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy. ...